• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Current status of the focused series "Urothelial Carcinoma".

作者信息

Yuk Hyeong Dong, Kim Hyung Suk, Ku Ja Hyeon

机构信息

Department of Urology, Seoul National University Hospital, Seoul, Korea. (Email:

Department of Urology, Dongguk University Ilsan Medical Center, Goyang-si, Gyeonggi-do, Korea. (Email:

出版信息

Transl Cancer Res. 2020 Oct;9(10):6534-6536. doi: 10.21037/tcr-2020-uc-10.

DOI:10.21037/tcr-2020-uc-10
PMID:35117262
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8798415/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a28/8798415/a141ab945c52/tcr-09-10-6534-fc.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a28/8798415/b2894f746298/tcr-09-10-6534-fa.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a28/8798415/dcd78e2ba34d/tcr-09-10-6534-fb.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a28/8798415/a141ab945c52/tcr-09-10-6534-fc.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a28/8798415/b2894f746298/tcr-09-10-6534-fa.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a28/8798415/dcd78e2ba34d/tcr-09-10-6534-fb.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a28/8798415/a141ab945c52/tcr-09-10-6534-fc.jpg

相似文献

1
Current status of the focused series "Urothelial Carcinoma".聚焦系列“尿路上皮癌”的现状
Transl Cancer Res. 2020 Oct;9(10):6534-6536. doi: 10.21037/tcr-2020-uc-10.
2
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?HER2/neu表达能否为晚期尿路上皮癌患者提供预后信息？
Cancer. 2002 Sep 1;95(5):1009-15. doi: 10.1002/cncr.10808.
3
Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up.终末期马兜铃酸肾病肾移植术后膀胱尿路上皮癌的迟发：一项长达15年随访的病例系列研究
Am J Kidney Dis. 2008 Mar;51(3):471-7. doi: 10.1053/j.ajkd.2007.11.015.
4
Managing noninvasive recurrences after definitive treatment for muscle-invasive bladder cancer or high-grade upper tract urothelial carcinoma.肌肉浸润性膀胱癌或高级别上尿路尿路上皮癌根治性治疗后非侵袭性复发的管理。
Curr Opin Urol. 2015 Sep;25(5):468-75. doi: 10.1097/MOU.0000000000000201.
5
Polypoid/papillary cystitis: a series of 41 cases misdiagnosed as papillary urothelial neoplasia.息肉样/乳头状膀胱炎：41例被误诊为乳头状尿路上皮肿瘤的病例系列
Am J Surg Pathol. 2008 May;32(5):758-64. doi: 10.1097/PAS.0b013e31816092b5.
6
Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma: Clinicopathologic Series of 16 Cases.具有滋养层分化的尿路上皮癌，包括绒毛膜癌：16 例临床病理系列。
Am J Surg Pathol. 2020 Oct;44(10):1322-1330. doi: 10.1097/PAS.0000000000001532.
7
Behavior of urothelial carcinoma with respect to anatomical location.尿路上皮癌在解剖学位置方面的表现。
J Urol. 2007 May;177(5):1715-20. doi: 10.1016/j.juro.2007.01.030.
8
Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases.膀胱肉瘤样尿路上皮癌：37例病例的当代临床病理分析
Can J Urol. 2015 Jun;22(3):7783-7.
9
Urothelial carcinoma of the prostate.前列腺尿路上皮癌
Urology. 2007 Jan;69(1 Suppl):50-61. doi: 10.1016/j.urology.2006.05.059.
10
Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.膀胱和前列腺的小细胞癌：TERT 启动子突变状态可区分恶性部位，并为膀胱小细胞癌和尿路上皮癌之间的共同克隆性提供证据。
Eur Urol Focus. 2018 Dec;4(6):880-888. doi: 10.1016/j.euf.2017.03.007. Epub 2017 Mar 31.

本文引用的文献

1
Survival benefit of neoadjuvant chemotherapy in pathologic T2N0 or lower urothelial carcinoma patients: evidence to support the use of neoadjuvant chemotherapy.新辅助化疗对病理分期为T2N0或更低的尿路上皮癌患者的生存获益：支持使用新辅助化疗的证据
Transl Androl Urol. 2020 Jun;9(3):1270-1277. doi: 10.21037/tau-19-705.
2
A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.一种基于无创尿液的甲基化生物标志物组合，用于检测膀胱癌并区分癌症分级。
Urol Oncol. 2020 Jun;38(6):603.e1-603.e7. doi: 10.1016/j.urolonc.2020.01.007. Epub 2020 Feb 18.
3
Cancer statistics, 2020.
癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
4
PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis.铂类治疗后进展的转移性尿路上皮癌的PD-L1/PD-1生物标志物：一项系统评价和荟萃分析。
Bladder Cancer. 2019 Nov 22;5(3):211-223. doi: 10.3233/BLC-190238.
5
Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification.根据 BASQ 分类的肌层浸润性膀胱癌的临床结局。
BMC Cancer. 2019 Sep 9;19(1):897. doi: 10.1186/s12885-019-6042-1.
6
Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.卡介苗无应答非肌肉浸润性膀胱癌的新兴免疫治疗选择。
J Urol. 2019 Dec;202(6):1111-1119. doi: 10.1097/JU.0000000000000297. Epub 2019 May 1.
7
Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Non-muscle Invasive Bladder Cancer Patients: Initial Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor Setting.中性粒细胞与淋巴细胞比值升高预示非肌层浸润性膀胱癌患者预后不良：经尿道膀胱肿瘤切除术后初始膀胱内卡介苗治疗情况
Front Oncol. 2019 Jan 17;8:642. doi: 10.3389/fonc.2018.00642. eCollection 2018.
8
Prognostication in Patients Treated with Radical Cystectomy for Urothelial Bladder Carcinoma: A New Simplified Model Incorporating Histological Variants.接受根治性膀胱切除术治疗的尿路上皮膀胱癌患者的预后评估：一种纳入组织学变体的新型简化模型
Bladder Cancer. 2018 Apr 26;4(2):195-203. doi: 10.3233/BLC-170156.
9
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.非转移性肌肉浸润性膀胱癌治疗：AUA/ASCO/ASTRO/SUO 指南。
J Urol. 2017 Sep;198(3):552-559. doi: 10.1016/j.juro.2017.04.086. Epub 2017 Apr 26.